论文部分内容阅读
目的 :评价力克肺疾作为初治肺结核治疗方案基本用药的疗效、患者合作情况和应用前景。方法 :选择 134例初治涂阳肺结核患者 ,以 1∶1随机分为治疗组 (2DRZ/ 4DR 6 9例 )和对照组 (2HRZ/ 4HR 6 5例 )进行短程化疗。结果 :治疗组和对照组 2个月痰菌阴转率分别为 91.3%和 75 .3% ;满疗程痰菌阴转率为 97.1%和 95 .4% ;X线全胸片显示两组病灶吸收分别占 95 .6 %和 78.5 %。空洞闭合分别为 6 6 .7%和 6 7.7%。两组药物不良反应发生率分别为 8.8%和 7.7% ;治疗组和对照组停药率分别为 5 .5 %和 6 .8%。结论 :力克肺疾是一种安全、高效、方便、易被患者接受、毒副作用小 ,可作为抗结核治疗的基本药物之一。
OBJECTIVE: To evaluate the efficacy of Lectra Pulmonary Diseases as a basic treatment for initial treatment of tuberculosis, cooperation among patients and its application prospect. Methods: A total of 134 newly diagnosed smear-positive pulmonary tuberculosis patients were selected and randomly divided into treatment group (2 DRZ / 4DR 6 9 cases) and control group (2HRZ / 4HR 6 5 cases) for short-course chemotherapy. Results: The sputum negative conversion rates of the treatment group and the control group were 91.3% and 75.3% respectively for 2 months; the sputum negative conversion rates were 97.1% and 95.4% for the full course of treatment; Absorption accounted for 95.6% and 78.5% respectively. Empty closures were 6.6% and 6.7% respectively. Adverse drug adverse reactions in the two groups were 8.8% and 7.7%, respectively. The withdrawal rates in the treatment and control groups were 5.5% and 6.8%, respectively. Conclusion: Lectra Pulmonary Disease is a safe, efficient, convenient and easily accepted by patients with little side effects and can be used as one of the basic drugs for anti-TB treatment.